|
OPA1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.50159901074676E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.73470024403366E-10 |
| Normal-vs-Stage2 |
4.344300E-03 |
| Normal-vs-Stage3 |
2.16360040994346E-10 |
| Normal-vs-Stage4 |
4.47979986439861E-10 |
| Stage1-vs-Stage2 |
4.610300E-02 |
| Stage1-vs-Stage3 |
2.223000E-01 |
| Stage1-vs-Stage4 |
9.262400E-02 |
| Stage2-vs-Stage3 |
1.199590E-02 |
| Stage2-vs-Stage4 |
6.699500E-03 |
| Stage3-vs-Stage4 |
4.869000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.27331478694259E-12 |
| Normal-vs-AfricanAmerican |
1.464040E-03 |
| Normal-vs-Asian |
1.51289999972271E-07 |
| Caucasian-vs-AfricanAmerican |
2.219600E-01 |
| Caucasian-vs-Asian |
9.770800E-01 |
| AfricanAmerican-vs-Asian |
2.851600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.47419965124129E-10 |
| Normal-vs-Female |
5.67159985642718E-10 |
| Male-vs-Female |
3.759400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.90130000632394E-09 |
| Normal-vs-Age(41-60Yrs) |
1.36709976672478E-10 |
| Normal-vs-Age(61-80Yrs) |
8.90270000053484E-07 |
| Normal-vs-Age(81-100Yrs) |
1.249530E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.910800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.259000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.564600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.672790E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.929200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.028800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.528190E-01 |
| Classical-VS-Follicular |
1.065240E-01 |
| Classical-VS-Other |
1.209650E-01 |
| Classical-VS-Normal |
7.23809900904371E-11 |
| Tall-VS-Follicular |
1.706340E-02 |
| Tall-VS-Other |
3.913000E-01 |
| Tall-VS-Normal |
1.76370000048998E-07 |
| Follicular-VS-Other |
8.568000E-02 |
| Follicular-VS-Normal |
3.766800E-04 |
| Other-VS-Normal |
2.633000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.6413999593421E-09 |
| Normal-vs-N1 |
3.31159988320451E-10 |
| N0-vs-N1 |
9.524500E-02 |
|
|
